Abaloparatide vs Teriparatide
Abaloparatide (Parathyroid hormone-related peptide analog) and Teriparatide (Parathyroid hormone (1–34) analog) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Page updated 2026-09-20. Latest review of a source entry: 2026-09-20. Editorial method.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Abaloparatide | Teriparatide |
|---|---|---|
| Compound class | Parathyroid hormone-related peptide analog | Parathyroid hormone (1–34) analog |
| Research category | Specialty & Research | Specialty & Research |
| Length (amino acids) | Not documented | Not documented |
| Molecular weight | Not documented | Not documented |
| Half-life | Not documented | Not documented |
| Origin | The phase 3 ACTIVE trial studied postmenopausal women with osteoporosis, using placebo and an open-label teriparatide group as comparators. Its primary endpoint concerned new vertebral fractures. | The 2001 fracture-prevention trial studied parathyroid hormone (1–34) in postmenopausal women with osteoporosis. It measured new fractures and bone mineral density, making it a foundational clinical comparator for bone-active peptide research. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Abaloparatide works
Abaloparatide is a peptide analog related to the parathyroid hormone pathway, studied in bone-formation research.
How Teriparatide works
Teriparatide represents the biologically active 1–34 fragment of parathyroid hormone and is studied in bone-remodeling contexts.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Abaloparatide
Teriparatide
What sets each apart
Abaloparatide
Fracture endpoints and bone mineral density are different outcomes. The open-label teriparatide arm should not be treated as a fully blinded head-to-head comparison.
Teriparatide
The cited trial concerns a defined osteoporosis population. It does not establish generalized recovery or performance benefits, or equivalence with research-supplier material.
Frequently asked questions
What is the evidence context for Abaloparatide?
Fracture endpoints and bone mineral density are different outcomes. The open-label teriparatide arm should not be treated as a fully blinded head-to-head comparison.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
What is the evidence context for Teriparatide?
The cited trial concerns a defined osteoporosis population. It does not establish generalized recovery or performance benefits, or equivalence with research-supplier material.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.
Linked publications
Publications recorded on each compound's profile, including original studies and reviews. These are background sources for the separate compounds; listing them together does not establish a direct comparison, a combination study, or equivalent evidence. Read the study design and limitations before interpreting a finding.